Instrument Inactif

Communiqués Audentes Therapeutics, Inc.

Actions

US05070R1041

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

AUDENTES THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	15/01/20	AQ
AUDENTES THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	16/12/19	AQ
WeissLaw LLP Investigates Audentes Therapeutics, Inc.	04/12/19	PR
AUDENTES THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	03/12/19	AQ
Astellas Pharma : to buy U.S. biotech firm for $3 bil. to boost gene therapy	03/12/19	AQ
Audentes Therapeutics : Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics	03/12/19	BU
Audentes Therapeutics : to Participate in Upcoming Investor Conferences	26/11/19	BU
Audentes Therapeutics : Reports Third Quarter 2019 Financial Results and Provides Corporate Update	07/11/19	BU
Audentes Therapeutics : to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2019	31/10/19	BU
Audentes Therapeutics : Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society	05/10/19	BU
Audentes Therapeutics : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/10/19	BU
Audentes Therapeutics : to Participate in Upcoming Investor Conferences	01/10/19	BU
Audentes Therapeutics : Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including New Data From ASPIRO, the Clinical Trial Evaluating AT132 in Patients With X-Linked Myotubular Myopathy (XLMTM)	30/09/19	BU
Audentes Therapeutics : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	07/09/19	BU
Audentes Therapeutics : to Participate in Upcoming Investor Conferences	26/08/19	PR
Audentes Therapeutics : to Participate in Upcoming Investor Conferences	01/08/19	PR
Audentes Therapeutics : to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 6, 2019	30/07/19	PR
Audentes Therapeutics : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20/07/19	PR
Audentes Therapeutics : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	08/06/19	PR
Audentes Therapeutics : Announces Changes to Senior Management Team	29/05/19	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Audentes Therapeutics, Inc.

Actions

US05070R1041

Communiqués

Filtres